Treatment of pancreatic fistula with the somatostatin analogue SMS 201-995

✍ Scribed by Dr. B. Ahrén; K.-G. Tranberg; S. Bengmark

• Publisher: John Wiley and Sons
• Year: 1988
• Tongue: English
• Weight: 160 KB
• Volume: 75
• Category: Article
• ISSN: 0007-1323
• DOI: 10.1002/bjs.1800750732

✦ Synopsis

Somatostatin inhibits exocrine pancreatic and has been used for treatment of pancreatic f i ~t u l a ~-~.

The short ti, < 3 m i n in man6, and the risk of a rebound effect when treatment is interrupted7, require the peptide to be continuously infused intravenously. This may be circumvented by using the stable somatostatin analogue SMS 201-995 (Sandostatin), a fragment of somatostatin with full biological effect but with resistance to the degrading enzymes*. In man, this analogue, which can be administered subcutaneously, has been demonstrated to exert the biological actions of somatostatin', including the inhibition of exocrine pancreatic se~retion','~. We describe here the use of SMS 201-995 for treating a patient with a postoperative pancreatic fistula.